Compare Synopsys, Inc. (SNPS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs TransMedics Group Inc — how do they compare? Synopsys, Inc. trades at $390 (market cap $72.47B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Synopsys, Inc. is far larger — about 28.5× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| SNPS | TMDX | |
|---|---|---|
Market Cap | $72.47B | $2.54B |
Sector | Technology | Technology |
52-Week High | $645.59 | $150.42 |
52-Week Low | $378.46 | $61.99 |
Enterprise Value | $80.82B | $2.94B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
